Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
US Stock Alert: Planet Labs drops 4% pre-market as Q1 business growth beats expectations but profitability indicators worsen

US Stock Alert: Planet Labs drops 4% pre-market as Q1 business growth beats expectations but profitability indicators worsen

格隆汇格隆汇2026/06/05 08:49
Show original
Glonghui June 5th|American commercial satellite company Planet Labs (PL.US) fell 4% in pre-market trading. According to reports, Planet Labs’ Q1 fiscal 2027 revenue was $94.2 million, up 42% year-on-year and exceeding market expectations of $90 million. The growth was mainly driven by demand from government and defense customers. Backlog orders exceeded $906 million, a 72% year-on-year surge, providing strong visibility for future revenue. However, GAAP net loss was $138.9 million, much higher than $12.6 million in the same period last year. The main reason for the widening loss was not a deterioration in business, but a non-cash book loss of about $106.5 million caused by a warrant revaluation resulting from a rise in the stock price. Adjusted EBITDA loss was $1 million, compared with a profit of $1.2 million in the same period last year.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage